In a 55-year-old woman with catatonia who was on two selective serotonin reuptake inhibitors until 36 hours ago, treated with lorazepam 6 mg daily, and now after three weeks shows residual bradykinesia, reduced blinking, and cogwheel rigidity following prior trifluoperazine use, what is the appropriate next management and should levodopa be used?

Management of Drug-Induced Parkinsonism Following Trifluoperazine in Catatonia

The residual parkinsonian symptoms (bradykinesia, reduced blinking, cogwheel rigidity) represent drug-induced parkinsonism from prior trifluoperazine exposure, and should be treated with an anticholinergic agent (such as benztropine or trihexyphenidyl) or amantadine—NOT levodopa, which is explicitly contraindicated in antipsychotic-induced parkinsonism.

Clinical Reasoning

This patient presents with a clear case of drug-induced parkinsonism secondary to trifluoperazine (a high-potency typical antipsychotic), superimposed on resolving catatonia. The clinical picture requires careful differentiation:

Key Diagnostic Considerations

• Catatonia is improving with lorazepam (better movements, conversations after 3 weeks)
• Parkinsonian features persist despite catatonia resolution, indicating these are medication side effects rather than catatonic symptoms
• The FDA label for trifluoperazine explicitly describes "pseudoparkinsonism" with mask-like facies, tremors, cogwheel rigidity, and shuffling gait 1
• Guidelines note that differentiating drug-induced parkinsonism from catatonia can be difficult, but improvement in other catatonic features with persistent motor symptoms points to extrapyramidal side effects 2

Specific Management Algorithm

Step 1: Continue Lorazepam

• Maintain current dose of 6 mg/day for catatonia
• The catatonia is responding appropriately and requires continued treatment 3

Step 2: Treat Drug-Induced Parkinsonism

First-line options (choose one):

• Anticholinergic agents: Benztropine 1-2 mg twice daily OR trihexyphenidyl 2-5 mg twice daily 4
• Amantadine: 100 mg twice daily (mild dopaminergic agent) 2, 4

Critical contraindication: The FDA label explicitly states "Levodopa has not been found effective in pseudoparkinsonism" caused by antipsychotics 1. Guidelines consistently recommend anticholinergic agents or amantadine, NOT levodopa, for drug-induced parkinsonism 2, 4.

Step 3: Monitor and Reassess

• Evaluate response after 2-3 weeks of antiparkinsonian treatment 2
• If symptoms persist despite adequate trial, consider switching from anticholinergic to amantadine or vice versa
• Reassess need for antiparkinsonian agents after several weeks to months, as many patients no longer require them long-term 2

Important Caveats

Why NOT Levodopa?

The evidence is unequivocal that levodopa should be avoided:

• FDA drug label specifically contraindicates it for antipsychotic-induced parkinsonism 1
• Levodopa could theoretically worsen psychotic symptoms or precipitate hypomanic episodes (relevant given her history of infrequent hypomanic symptoms)
• The mechanism of drug-induced parkinsonism is dopamine receptor blockade, not dopamine deficiency as in Parkinson's disease

Risk of Neuroleptic Malignant Syndrome (NMS)

Monitor carefully for NMS features, as this patient has multiple risk factors:

• Recent antipsychotic exposure (trifluoperazine)
• Catatonic presentation
• Rigidity already present
• NMS presents with hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability 4, 1

Psychiatric Medication Considerations

Given her history of:

• Two SSRIs discontinued 36 hours ago
• Infrequent hypomanic symptoms
• Catatonia

Avoid reintroducing antipsychotics unless absolutely necessary for psychosis. If mood stabilization is needed after catatonia resolves, consider mood stabilizers rather than antipsychotics given her vulnerability to extrapyramidal symptoms.

Duration of Antiparkinsonian Treatment

• Generally requires 2-3 months of treatment 2, 1
• Periodically attempt to taper and discontinue, as symptoms often resolve with time after antipsychotic discontinuation
• Some patients may require longer treatment if symptoms persist

Monitoring Parameters

• Weekly assessment of parkinsonian symptoms using standardized scales
• Bush-Francis Catatonia Rating Scale to ensure catatonia continues improving
• Vital signs and autonomic function to screen for NMS
• Mental status for emergence of psychotic or hypomanic symptoms
• Anticholinergic side effects if using benztropine/trihexyphenidyl (dry mouth, constipation, urinary retention, confusion)